Trial Profile
An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary) ; Raloxifene
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Sanofi
- 17 Jan 2011 New trial record